SEC Filing Document

Company: BIOVENTRIX, INC.
Ticker: 
CIK: 1283259
Filing Type: S-1/A
Document Type: S-1/A
Date Filed: 2026-03-18
Accession Number: 0001493152-26-010642
Exchange: 
SIC Code: 3841
SIC Description: Surgical & Medical Instruments & Apparatus
URL: https://www.sec.gov/Archives/edgar/data/1283259/000149315226010642/forms-1a.htm

Chunk 60 of 85
Word Count: 1481
Character Count: 9417

Document Content:

shares of common stock held by Michael N. Taglich Keogh Account, (i) 3,179 shares of common stock held by Michael Taglich TTEE Hope A Taglich Supplemental Needs Trust UAD 8/23/17, and (j) 677,500 Series A shares convertible into common stock held by Bioventrix investors LLC. Mr. Taglich is the President of Taglich Brothers Inc., Michael N. Taglich Keogh Account, Michael Taglich TTEE Hope A Taglich Supplemental Needs Trust UAD 8/23/17, and Bioventrix investors LLC and has voting and investment control over the shares held by Michael N. Taglich & Claudia Taglich, Claudia Ruggiero Taglich, Michael Taglich C/F Amanda Taglich UTMA NY, Michael Taglich C/F Lucy Taglich UTMA NY, and Michael Taglich C/F Stella Taglich UTMA NY (collectively, the “Taglich Entities”). Mr. Taglich disclaims any beneficial ownership of the securities held by the Taglich Entities, other than to the extent of any pecuniary interest he may have therein, directly or indirectly.

(6)	Includes
(a) 165,000 common shares directly held by Mr. Ravich (including 57,750 common shares from Second RSA Grant 2024 and 41,250 common
shares from Second RSA Grant 2025), (b) 10,000 common shares comprised of 10,000 Series A shares held by Mark Ravich Irrevocable
Trust, (c) 228,954 common shares comprised of 79,880 Series A shares, $133,042 Secured Convertible Notes, and $16,032
Series A-1 Secured Convertible Notes held by Mark Ravich Revocable Trust, (d) 372,406 common shares comprised of 93,590 common
shares, 10,000 Series A shares, and $268,816 Secured Convertible Notes held by Mark Ravich TTEE Mark Ravich Irrevocable Trust
UAD 11/05/18, (e) 87,938 common shares held by Mark H. Ravich TTEE Revocable Trust of Mark H. Ravich UAD 10/08/19, (f) 71,255
common shares comprised of 5,000 Series A shares and $66,255 Secured Convertible Notes held by Norman and Sally Ravich Family
Trust, (g) 40,261 common shares held by Mark Ravich TTEE Cindy Libman Irrevocable Trust UAD 11/05/18, (h) 17,482 common shares held
by Mark H. Ravich TTEE Norman & Sally Ravich Family Trust UAD 12/24/92, (i) 8,123 common shares held by Alexander Coleman Ravich
1991 Irrevocable Trust, (j) 8,123 common shares held by Alyssa Danielle Ravich 1991 Irrevocable Trust, and (k) 5,475 common shares
held by Ilyne Ravich. Mr. Ravich is the Trustee and has voting and investment control of Mark Ravich Irrevocable Trust, Revocable
Trust of Mark Ravich, Mark Ravich TTEE Mark Ravich Irrevocable Trust UAD 11/05/18, Mark H. Ravich TTEE Revocable Trust of Mark H.
Ravich UAD 10/08/19, Norman and Sally Ravich Family Trust, Mark Ravich TTEE Cindy Libman Irrevocable Trust UAD 11/05/18, Mark H.
Ravich TTEE Norman & Sally Ravich Family Trust UAD 12/24/92, Alexander Coleman Ravich 1991 Irrevocable Trust, and Alyssa Danielle
Ravich 1991 Irrevocable Trust (collectively, the “Ravich Entities”). Mr. Ravich disclaims any beneficial ownership of
the securities held by the Ravich Entities, other than to the extent of any pecuniary interest he may have therein, directly or indirectly.

(7)	For
note conversions into shares assumes that interest accrues through November 30, 2025 on the
March 2024 Through August 2024 Series A Secured Convertible Note Financing and the October
2024 Through September 2025 Series A-1 Secured Convertible Note Financing.

(8)	The
Secured Convertible Notes convert into our common stock subject to an initial public offering
generating $7.5 million of gross proceeds. We have assumed the initial public offering price
is at least $10.00 per share, generating gross proceeds of $[   ]. Each
$1.00 decrease in the assumed initial public offering price of $
per share (the midpoint of the estimated price range set forth on the cover page of this
prospectus) below $10.00 per share would increase the number of shares issued upon
the conversion by approximately $        , assuming the
number of shares, as set forth on the cover page of this prospectus, remains the same and
after deducting underwriting discounts and estimated offering expenses payable by us.

CERTAIN
RELATIONSHIPS AND RELATED PARTY TRANSACTIONS

During
the period from January 1, 2023 to the date of this prospectus, we have entered into or participated in the following transactions with
related persons:

On January 2, 2026, the
Company granted 90,000 restricted stock awards to the three independent members of the Company’s board of directors, valued at
$1.14 per share, of which 3,750 will vest each month through December 2027.

On October 1, 2025,
the Company granted 422,500 stock options at an exercise price of $1.14 per share. The options vest 105,625 after one year
and, thereafter, 8,802 of the option shares shall vest at the end of each full month over thirty-six (36) consecutive months.
Certain of the Company’s executive officers and members of the board were granted 265,000 of the 422,500 stock options
granted.

On January 15, 2025, Mr. Chartier,
our Co-Chief Executive Officer and President, was granted 220,000 stock options at an exercise price of $1.00 per share. The option
shares vest 55,000 after one year and, thereafter, 4,583 of the option shares shall vest at the end of each full month
over thirty-six (36) consecutive months.

On January 1, 2025,
Mr. Richmond, our Co-Chief Executive Officer and Chief Financial Officer was granted 191,000 stock options at an exercise price of
$1.00 per share. The option shares vest 47,750 after one year and, thereafter, 3,979 of the option shares shall vest at the end of
each full month over thirty-six (36) consecutive months.

In March 2024, officers
and directors received 348,000 shares of restricted stock awards, 232,000 shares valued at $0.80 per share vested immediately.

In March 2024, Mr. Richmond, our Co-Chief Executive Officer and Chief Financial Officer
and entities controlled by him purchased $1,830,000 Series A Secured Convertible Notes from us.

In February 2024, Mr.
Taglich and Mr. Richmond and entities controlled by them purchased 650,000 Preferred Series A shares from other investors Mr. Taglich and Mr. Richmond subsequently sold 195,780 of these shares to us at cost to be used as incentive for certain purchasers of Series A Secured
Convertible Notes (the “Sweetener Shares”). We acquired an additional 30,120 Preferred Series A shares from Mr. Mark Ravich
for a total of 225,900 Sweetener Shares.

March 20, 2023, we entered into a Voting Agreement with holders of the Series A Preferred Stock. According to its terms, the Voting Agreement
will terminate upon the closing of this offering.

March 2022, we entered into a placement agent agreement with Taglich Brothers, Inc. (“Taglich Brothers”), when Michael Taglich
was a director at BioVentrix. Under the agreement, Taglich Brothers, where Michael Taglich is an owner, acted as the exclusive placement
agent on a best-efforts basis for our Series B Preferred Stock financing, and was contracted to receive a 7% cash fee on new cash investments
and warrants equal to 10% of the underlying shares of common stock issuable upon conversion. Pursuant to this placement agent agreement,
Taglich Brothers received $1,320,053 in Series B Preferred Stock in 2023 which subsequently converted to 587 shares of common
in the February 2023 recapitalization. See “Description of Capital Stock — History of Securities Issuances — February
2023 Recapitalization.”

Policies
and Procedures with Respect to Related Party Transactions

Pursuant
to the audit committee charter to be adopted upon closing of this offering, our audit committee will be responsible for reviewing and
approving transactions with related persons. A related person includes directors, executive officers, beneficial owners of 5% or more
of any class of our voting securities, immediate family members of any of the foregoing persons, and any entities in which any of the
foregoing is an executive officer or is an owner of 5% or more ownership interest.

a transaction involving an amount in excess of $120,000 has been identified as a related person transaction, including any transaction
that was not a related person transaction when originally consummated or any transaction that was not initially identified as a related
person transaction prior to consummation, information regarding the related person transaction will be reviewed by our audit committee,
which will determine whether to approve the transaction.

considering related person transactions, our audit committee will take into account the relevant available facts and circumstances including,
but not limited to:

●	the
related person’s interest in the related person transaction;

●	the
approximate dollar value of the amount involved in the related person transaction;

●	the
approximate dollar value of the amount of the related person’s interest in the transaction
without regard to the amount of any profit or loss;

●	whether
the transaction was undertaken in our ordinary course of business;

●	whether
the transaction with the related person is proposed to be, or was, entered into on terms
no less favorable to us than terms that could have been reached with an unrelated
third party;

●	the
purpose of, and the potential benefits to us of, the transaction; and

●	any
other information regarding the related person transaction or the related person in the context
of the proposed transaction that would be material to investors in light of the circumstances
of the particular transaction.